表达弓形虫MIC3、ROP9和SAG2的重组腺病毒疫苗可诱导小鼠抗急性弓形虫病的保护性免疫
研究构建表达TgMIC3、TgSAG2或TgROP9的重组腺病毒,免疫BALB/c小鼠后检测抗体水平、淋巴细胞及活化T淋巴细胞百分比、细胞因子产生、存活率和存活时间,以评估对急性弓形虫感染的保护效果。结果表明,二价或三价重组腺病毒免疫可强烈刺激小鼠体液和细胞免疫应答,对弓形虫RH速殖子致死性攻击产生有效免疫保护,其中Ad-ROP9-MIC3-EGFP可能是抗急性弓形虫感染的候选疫苗。
要点
- 二价或三价重组腺病毒可刺激小鼠体液和细胞免疫应答。
- 免疫小鼠对弓形虫RH速殖子致死性攻击产生有效保护。
- Ad-ROP9-MIC3-EGFP可能是抗急性弓形虫感染的候选疫苗。
核心结论
- 二价和三价重组腺病毒免疫可对小鼠急性弓形虫感染提供有效免疫保护。
- Ad-ROP9-MIC3-EGFP可能是抗急性弓形虫感染的候选疫苗。
研究设计与样本
- 研究构建表达TgMIC3、TgSAG2或TgROP9的重组腺病毒,并在BALB/c小鼠中评估其作为抗急性弓形虫感染疫苗的潜力。
- 免疫后检测抗体水平、淋巴细胞及活化T淋巴细胞百分比、细胞因子产生、存活率和存活时间以评价保护效果。
主要发现
- 二价或三价重组腺病毒免疫可强烈刺激小鼠体液和细胞免疫应答。
- 免疫小鼠对弓形虫RH速殖子致死性攻击产生有效免疫保护。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Toxoplasmosis is a worldwide zoonosis caused by the protozoan parasite Toxoplasma gondii, an obligate intracellular parasite. Currently, no viable vaccine or effective drug strategies exist to prevent and control toxoplasmosis. T. gondii microneme protein 3 (MIC3), rhoptry protein 9 (ROP9), and surface antigen 2 (SAG2) are related to active invasion of the parasite. Hence, we constructed recombinant adenoviruses expressing TgMIC3, TgSAG2, or TgROP9 and evaluated the recombinant adenoviruses as potential vaccines against acute T. gondii infection in BALB/c mice. Mice immunized with the recombinant adenoviruses were measured the antibody levels, percentages of lymphocytes and actived T lymphocytes, cytokine productions, and the survival rates and time to evaluate the protective efficacy. Results showed that immunization with the bivalent or trivalent recombiant adenoviruses could strongly stimulate humoral and cellular immune responses in mice, resulting in effective immune protections against lethal challenge with the tachyzoites of T. gondii RH. These results indicated that the divalent and trivalent adenoviruses, especially Ad-ROP9-MIC3-EGFP, may be promising vaccine candidates against acute T. gondii infection.
引用
- Zhang D, Jiang N, Chen Q, et al. Vaccination with recombinant adenoviruses expressing Toxoplasma gondii MIC3, ROP9, and SAG2 provide protective immunity against acute toxoplasmosis in mice. Vaccine. 2019. PMID: 30670302. doi:10.1016/j.vaccine.2018.12.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。